Tesamorelin
Tesamorelin (10mg / 20mg)
Vial Size
$285USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.288
Reference number
20mg
Lyophilized vial
Synthetic GHRH analog. FDA-approved version (Egrifta) indicated for HIV-associated lipodystrophy. Research analog for in vitro study.
Origin
Tesamorelin was developed by Theratechnologies Inc. of Montreal, Canada, as a stabilized analog of human GHRH(1-44). A trans-3-hexenoic acid modification at the N-terminus confers resistance to enzymatic degradation while preserving full GHRH receptor agonist activity.
Research Lineage
Falutz et al. published pivotal Phase III clinical trial results in 2007 and 2010, leading to FDA approval of the branded version Egrifta in 2010 for treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog with active FDA approval for a clinical indication. Research continues in visceral adiposity and hepatic steatosis.
Mechanism of Action
Tesamorelin binds to the GHRH receptor on anterior pituitary somatotrophs, stimulating endogenous GH synthesis and secretion. The N-terminal hexenoic acid group provides DPP-IV resistance. In clinical trials, it was observed to reduce trunk fat mass and visceral adipose tissue while preserving the GH feedback loop.
Structural Notes
44-amino-acid peptide with N-terminal trans-3-hexenoic acid modification. Molecular weight: ~5135 Da.
Key References
Falutz J et al. N Engl J Med. 2007;357(23):2359-70.
Falutz J et al. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.